Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value

$108.52+1.27 (+1.18%)

Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%

Abbott Laboratories statistics

112 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Jan 21, 2027 (estimated, before the open)
Last ex-dividend date: Oct 15, 2026
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $187.78B; $272.32M
Enterprise Value: $215.24B; $146.23M
PE Ratio: 40.19; 25.11
PS Ratio: 3.89; 3.66
PB Ratio: 3.68; 2.00
P/FCF Ratio: 27.79; 17.86
P/OCF Ratio: 21.21; 12.99

Enterprise valuationIndustry

EV / Sales: 4.46; 2.57
EV / EBITDA: 32.38; 16.50
EV / EBIT: 32.38; 19.31
EV / FCF: 31.85; 22.27

Share statisticsIndustry

Shares Outstanding: 1.73B; 58M
Shares Change (YoY): -0.27%; 10.8%
Float: 1.72B; 49M
Shares Held by Insiders: 0.50%; 11.7%
Shares Held by Institutions: 79.8%; 56.4%

Short sellingIndustry

Short Interest: 19M; –
Short Interest Change: 9.61%; -0.80%
Short % of Float: 1.11%; 9.01%
Short % of Shares Outstanding: 1.10%; 6.30%
Days to Cover: 1.91; 5.15

Stock price statisticsIndustry

52-Week High: $132.03; –
52-Week Low: $81.97; –
20-Day Moving Average: $106.96; –
50-Day Moving Average: $103.91; –
200-Day Moving Average: $101.56; –
Average True Range (14): $2.94; –
Price Change (1 Week): -1.28%; -1.15%
Price Change (1 Month): 3.67%; -4.87%
Price Change (3 Months): -1.68%; -21.0%
Price Change (6 Months): 28.5%; -20.6%
Price Change (YTD): -13.4%; -23.6%
Price Change (1 Year): -15.8%; -22.4%
Price Change (3 Years): 11.8%; -29.5%
Price Change (5 Years): -15.5%; -77.9%
Price Change (10 Years): 176.8%; -65.4%
Average Volume (10 Days): 9M; –
Average Volume (20 Days): 9M; –
Average Volume (90 Days): 10M; –
Relative Volume: 0.65; 0.70
Relative Strength Index (14): 54.1; 43.4
Volatility (1 Year): 28.4%; 80.1%
Beta (5 Years): 0.45; 1.07

MarginsIndustry

Gross Margin: 56.9%; 53.1%
Operating Margin: 13.8%; -38.7%
Pretax Margin: 13.6%; -11.6%
Profit Margin: 9.75%; -31.6%
EBITDA Margin: 13.8%; -27.7%
FCF Margin: 14.0%; -9.56%

Returns on capitalIndustry

Return on Equity (ROE): 9.22%; -49.9%
Return on Assets (ROA): 4.89%; -40.6%
Return on Invested Capital (ROIC): 7.10%; -32.9%
Return on Capital Employed (ROCE): 7.22%; -37.9%

Financial positionIndustry

Current Ratio: 1.45; 3.30
Quick Ratio: 0.83; 2.39
Debt / Equity: 0.61; 0.49
Debt / EBITDA: 4.69; 3.15
Debt / FCF: 4.61; 4.65
Net Debt / EBITDA: 4.04; 1.97
Interest Coverage: 6.68; -6.35

GrowthIndustry

Revenue Growth (YoY): 10.0%; 6.82%
Net Income Growth (YoY): -66.4%; -14.4%
EPS Growth (YoY): -66.2%; -12.3%
FCF Growth (YoY): -2.31%; 6.85%
Revenue Growth (3Y CAGR): 0.51%; 2.25%
Revenue Growth (5Y CAGR): 5.08%; 6.41%
EPS Growth (3Y CAGR): -1.65%; 1.30%
EPS Growth (5Y CAGR): 8.27%; 3.78%

EfficiencyIndustry

Asset Turnover: 0.50; 0.40
Inventory Turnover: 2.96; 2.73
Revenue Per Employee: $419.38K; $429.29K
Profits Per Employee: $40.88K; -$689.41K
Employee Count: 115,000; 74
WACC: 7.04%; 10.2%

Income statement (TTM)Industry

Revenue: $48.23B; $66.37M
Gross Profit: $27.46B; $120.78M
Operating Income: $6.65B; -$21.37M
Pretax Income: $6.56B; -$12.95M
Net Income: $4.70B; -$22.35M
EBITDA: $6.65B; -$17.21M
EPS (Diluted): $2.70; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $4.30B; $68.68M
Total Debt: $31.16B; $116.91M
Net Cash (Debt): -$26.86B; $17.76M
Net Cash Per Share: -$15.52; $0.80
Equity (Book Value): $51.03B; $53.89M
Book Value Per Share: $29.49; $1.50
Tangible Book Value: -$1.21B; $27.13M
Working Capital: $7.34B; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: $8.86B; -$12.38M
Capital Expenditures: -$2.10B; -$1.00M
Free Cash Flow: $6.76B; -$18.21M
FCF Per Share: $3.90; -$0.42

Dividends and yieldsIndustry

Earnings Yield: 2.50%; -21.8%
FCF Yield: 3.60%; -9.44%
Dividend Yield: 2.21%; 1.88%
Buyback Yield: 0.82%; -0.76%
Shareholder Yield: 3.03%; 0.00%
Dividend Per Share: $2.40; $0.83
Dividend Growth (YoY): 7.14%; 2.37%
Years of Dividend Growth: 3; 0
Payout Ratio: 92.0%; 55.4%
FCF Payout Ratio: 64.0%; 43.7%

Taxes and interestIndustry

Interest Expense: $995.00M; $2.90M
Income Tax: $1.86B; $73.00K
Effective Tax Rate: 28.4%; 20.9%

Scores and fair valueIndustry

Graham Number: $42.33; $19.34
Graham Upside: -61.0%; -46.6%
Altman Z-Score: 3.36; 0.23
Piotroski F-Score: 6; 4
Lynch Fair Value: $22.34; –
Lynch Upside: -79.4%; -28.9%

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	ABT	S&P 500	Difference	ABT per year	S&P 500 per year
1 month	+6.4%	-3.0%	+9.4 pts
3 months	-1.9%	-2.8%	+0.9 pts
Year to date	-11.2%	+11.5%	−22.7 pts
1 year	-14.0%	+13.5%	−27.4 pts
3 years	+20.7%	+77.7%	−57.0 pts	+6.5%	+21.1%
5 years	-6.7%	+72.6%	−79.3 pts	-1.4%	+11.5%
10 years	+226.3%	+308.2%	−81.9 pts	+12.6%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

19M ABT shares were sold short on Oct 30, 2026, up 9.6% from the previous report, or 1.11% of the shares available to trade. At recent volumes it would take 1.9 days to buy them back. Over the last 20 sessions, 41.7% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	19,058,208	+9.6%	9,959,167	1.9
Oct 15, 2026	17,386,736	+27.5%	9,768,072	1.8
Sep 30, 2026	13,634,256	-31.5%	9,340,141	1.5
Sep 15, 2026	19,911,199	-10.0%	7,733,955	2.6
Aug 31, 2026	22,129,750	+8.6%	8,303,321	2.7
Aug 14, 2026	20,375,133	-9.9%	7,134,921	2.9
Jul 31, 2026	22,624,184	-8.9%	13,625,912	1.7
Jul 15, 2026	24,846,147	+6.2%	11,611,821	2.1
Jun 30, 2026	23,387,895	+6.4%	15,812,969	1.5
Jun 15, 2026	21,974,266	-0.3%	12,404,150	1.8
May 29, 2026	22,044,423	-5.1%	11,365,242	1.9
May 15, 2026	23,222,031	+3.0%	13,666,024	1.7

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Abbott Laboratories's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jun 1, 1998
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABT.

Compare: ABT vs ABBV · ABT vs LLY · ABT vs JNJ · ABT vs PFE · ABT vs VTRS

Revenue growth10.0% · median 7.8%

Gross margin56.9% · median 71.5%

Operating margin13.8% · median 13.1%

Net margin9.7% · median 13.0%

Company	Revenue	Growth
JNJ	$99.34B	+7.8%
LLY	$86.46B	+45.5%
ABBV	$64.39B	+10.4%
PFE	$63.63B	+1.3%
ABT	$48.23B	+10.0%
VTRS	$14.73B	+4.3%

Company

Next earnings (est.): Jan 21, 2027, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 115,000
Held by institutions: 79.8%
Auditor: Ernst & Young LLP
SEC CIK: 1800

Advertisement
300 × 250

See a number that looks wrong?